GenMont Biotech Incorporation (TPE:3164)
Taiwan · Delayed Price · Currency is TWD 16.10
+0.25 (1.58%)
Aug 26, 2026, 1:30 PM CST
TPE:3164 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 382.11 | 401.23 | 385.37 | 318.02 | 368.55 | 427.93 | |
Revenue Growth | -1.11% | 4.11% | 21.18% | -13.71% | -13.88% | 31.59% |
Cost of Revenue | 154.6 | 149.6 | 147.19 | 106.82 | 111.83 | 128.6 |
Gross Profit | 227.5 | 251.63 | 238.18 | 211.19 | 256.72 | 299.33 |
Selling, General & Admin | 146.69 | 147.82 | 152.79 | 156.6 | 137.12 | 145.47 |
Research & Development | 44.52 | 45.34 | 45.27 | 46.86 | 59.41 | 25.52 |
Operating Expenses | 199.5 | 193.88 | 197.55 | 204.2 | 194.75 | 174.29 |
Operating Income | 28 | 57.75 | 40.63 | 6.99 | 61.97 | 125.04 |
Interest Expense | -3.82 | -3.92 | -3.72 | -0.97 | -0.76 | -0.77 |
Interest & Investment Income | 6.6 | 7.39 | 11.6 | 9.46 | 4.8 | 2.35 |
Currency Exchange Gain (Loss) | -3 | -3 | 17.05 | -6.98 | 10.45 | -1.35 |
Other Non Operating Income (Expenses) | 49.29 | 1.44 | 0.4 | 0.34 | -1.98 | 1.06 |
EBT Excluding Unusual Items | 77.07 | 59.67 | 65.97 | 8.83 | 74.48 | 126.34 |
Gain (Loss) on Sale of Investments | 4.02 | 4.02 | -1.23 | 19.05 | -8.16 | 9.35 |
Gain (Loss) on Sale of Assets | -0 | -0 | -0.02 | 0.28 | -0.06 | 3.74 |
Pretax Income | 81.09 | 63.68 | 64.72 | 28.16 | 66.26 | 139.42 |
Income Tax Expense | 21.83 | 15.7 | 16.97 | 5.73 | 18.8 | 29.82 |
Earnings From Continuing Operations | 59.26 | 47.98 | 47.75 | 22.43 | 47.46 | 109.6 |
Net Income to Company | 59.26 | 47.98 | 47.75 | 22.43 | 47.46 | 109.6 |
Minority Interest in Earnings | 9.91 | 9.22 | 9.5 | 10.56 | 9.52 | 3.53 |
Net Income | 69.17 | 57.2 | 57.25 | 32.99 | 56.98 | 113.13 |
Net Income to Common | 69.17 | 57.2 | 57.25 | 32.99 | 56.98 | 113.13 |
Net Income Growth | 344.72% | -0.09% | 73.53% | -42.10% | -49.64% | 85.82% |
Shares Outstanding (Basic) | 86 | 86 | 87 | 86 | 86 | 86 |
Shares Outstanding (Diluted) | 86 | 87 | 87 | 87 | 87 | 87 |
Shares Change | -0.29% | -0.23% | 0.18% | -0.10% | -0.09% | -1.50% |
EPS (Basic) | 0.80 | 0.66 | 0.66 | 0.38 | 0.66 | 1.31 |
EPS (Diluted) | 0.80 | 0.66 | 0.66 | 0.38 | 0.66 | 1.30 |
EPS Growth | 344.50% | 0% | 73.68% | -42.40% | -49.25% | 88.41% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 85.52 | 70.19 | 79.89 | 1.29 | 65.79 | -5.28 |
Free Cash Flow Per Share | 0.99 | 0.81 | 0.92 | 0.01 | 0.76 | -0.06 |
Dividend Per Share | 0.800 | 0.800 | 0.800 | 0.500 | 0.700 | 1.100 |
Dividend Growth | 0% | 0% | 60.00% | -28.57% | -36.36% | 57.14% |
Gross Margin | 59.54% | 62.72% | 61.80% | 66.41% | 69.66% | 69.95% |
Operating Margin | 7.33% | 14.39% | 10.54% | 2.20% | 16.81% | 29.22% |
Profit Margin | 18.10% | 14.26% | 14.86% | 10.37% | 15.46% | 26.44% |
Free Cash Flow Margin | 22.38% | 17.49% | 20.73% | 0.41% | 17.85% | -1.23% |
EBITDA | 91.63 | 120.57 | 108.18 | 68.77 | 109.92 | 143.05 |
EBITDA Margin | 23.98% | 30.05% | 28.07% | 21.63% | 29.82% | 33.43% |
D&A For EBITDA | 63.63 | 62.81 | 67.55 | 61.79 | 47.95 | 18.02 |
EBIT | 28 | 57.75 | 40.63 | 6.99 | 61.97 | 125.04 |
EBIT Margin | 7.33% | 14.39% | 10.54% | 2.20% | 16.81% | 29.22% |
Effective Tax Rate | 26.92% | 24.65% | 26.22% | 20.35% | 28.37% | 21.39% |